P.O. Box 50
Auckland, New Zealand
Phone: +64 9 373 5600

James Watson, CEO


Genesis Research and Development Corp. Ltd. partners with pharmaceutical, biotechnology, agricultural and forestry companies to develop and market end products from its gene discovery pipeline. The company has built a genomics technology platform to identify new molecules that regulate the distribution of information during cell-to-cell communication common to all life systems, from microbes to plants and animals.

Its core scientific technologies include database construction, cDNA libraries and DNA sequencing, along with the use of bioinformatics and high-throughput screening. The protein therapeutics program is aimed at identifying transcription regulators and cytokines involved in development and function of the immune system and skin. Its plant program focuses on transcription factors controlling gene expression in targeted plants and plant signaling molecules that regulate cell-to-cell communication in plants and communication between plants and the environment.

Genesis Research has three product candidates: a vaccine for psoriasis, a vaccine for asthma and a target molecule for lignin modification in forestry trees.


Partners include Corixa Corp., Immunex Corp., Zenyaku Kogyo Co. Ltd., AgResearch Ltd., Fletcher Challenge Forests Ltd., International Paper, SR Pharma plc, Westvaco Corp., Wrightson Ltd., The Horticulture and Food Research Institute of New Zealand Ltd. and The New Zealand Dairy Board.